美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察  

Clinical efficacy of metoprolol combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure

作　　者：李心畅[1] 吴迪[1] 段庆辉 李迪[1] LI Xinchang;WU Di;DUAN Qinghui;LI Di(Department of Cardiology, Daqing Oilfield General Hospital, Daqing 163001, China)

机构地区：[1]大庆油田总医院心内科

出　　处：《中国现代医生》2019年第18期49-51,共3页China Modern Doctor

摘　　要：目的观察美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效。方法选取2016年8月~2018年8月我院住院治疗的冠心病心力衰竭患者60例,均经冠脉造影和超声检查确诊,其中男32例,女28例,年龄48~72岁,全部患者随机分为观察组和对照组,每组各30例,两组均予以常规对症支持治疗,观察组同时联合美托洛尔联合曲美他嗪治疗,治疗后对比分析两组的临床疗效、两组患者各项心功能指标变化情况。结果观察组患者治疗后的总有效率为96.7%(29/30),对照组患者治疗后的总有效率为70.0%(21/30),两组临床疗效比较,差异具有显著性(P<0.05)。两组患者治疗后的SBP、DBP及HR、LVESD、LVEDD水平显著低于治疗前,差异具有显著性(P<0.05),但两组患者治疗后的LVEF水平较治疗前明显提高,差异具有显著性(P<0.05);治疗后两组患者的SBP、DBP及HR、LVESD、LVEDD水平均显著低于对照组,LVEF水平均显著高于对照组,差异具有显著性(P<0.05)。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效确切,心功能改善明显,临床症状得到明显缓解,值得广泛推广和应用。Objective To observe the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease with heart failure. Methods Sixty patients with coronary heart disease and heart failure who were hospitalized in our hospital from August 2016 to August 2018 were enrolled. All patients were diagnosed by coronary angiography and ultrasonography, including 32 males and 28 females, aged 48-72 years. All patients were randomly divided into observation group and control group, with 30 cases in each group. Both groups were treated with conventional symptomatic support. The observation group was also treated with metoprolol combined with trimetazidine at the same time. The clinical efficacy, the changes in cardiac function indicators of the two groups after treatment between the two groups were compared. Results The total effective rate of the observation group was 96.7%(29/30) after treatment. The total effective rate of the control group after treatment was 70.0%(21/30). The difference in clinical efficacy between the two groups was significant(P<0.05). The levels of SBP, DBP and HR, LVESD, and LVEDD in the two groups after treatment were significantly lower than those before treatment(P<0.05). But the LVEF levels in the two groups were significantly higher than those before treatment, and the difference was significant(P<0.05). The SBP, DBP and HR,LVESD, and LVEDD levels in the observation group after treatment were significantly lower than those in the control group. The LVEF level in the observation group was significantly higher than that in the control group(P<0.05). Conclusion Metoprolol combined with trimetazidine is effective in the treatment of coronary heart disease with heart failure.The cardiac function is improved obviously, and the clinical symptoms are obviously relieved. It is worthy of widespread promotion and application.

关 键 词：冠心病心力衰竭 美托洛尔 曲美他嗪 心功能 

分 类 号：R541.4[医药卫生—心血管疾病] R541.6[医药卫生—内科学]